How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

628 results for

Dihydroergotamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD<sup>®</sup> ) Device, in Healthy Adult Subjects. (PubMed)

STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects. Investigate the safety and pharmacokinetics (PK) of INP104, intranasal dihydroergotamine mesylate (DHE) administered via a Precision Olfactory Delivery (POD® ) device, (Impel NeuroPharma, Seattle, WA) vs intravenous (IV) DHE and DHE nasal spray (Migranal®

2019 Headache

2. Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors (PubMed)

Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors Dihydroergotamine (DHE) is an antimigraine drug that produces cranial vasoconstriction and inhibits trigeminal CGRP release; furthermore, it inhibits the vasodepressor sensory CGRPergic outflow, but the receptors involved remain unknown. Prejunctional activation of α2A/2C-adrenergic, serotonin 5-HT1B/1F, or dopamine D2-like receptors results in inhibition

Full Text available with Trip Pro

2018 The journal of headache and pain

3. Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment. (PubMed)

Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment. To review whether the incidence of catheter-associated venous thromboses was higher in patients receiving IV dihydroergotamine compared to lidocaine.We retrospectively reviewed all admissions at the University of California, San Francisco Headache Center from February 25, 2008, through October 31, 2014, for age, sex, diagnosis, aura, treatment dose, type of IV line used, days with line, superficial (...) (SVT) or deep venous thrombosis (DVT), and pulmonary embolism (PE).A peripherally inserted central catheter (PICC) or midline catheter was placed in 315 of 589 (53%) admissions. Mean age was 38 years with a range of 6 to 79 years; 121 patients (21%) were ≤18 years old. Seventy-four percent (433 of 589) of patients were female. Of 263 dihydroergotamine admissions using a PICC or midline catheter, 19 (7.2%) had either an SVT or DVT or a PE; 2 patients were diagnosed with both DVT and PE. Of 52

Full Text available with Trip Pro

2017 Neurology

4. The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats (PubMed)

The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats Dihydroergotamine (DHE) is an acute antimigraine agent that displays affinity for dopamine D2-like receptors, serotonin 5-HT1/2 receptors and α1/α2-adrenoceptors. Since activation of vascular α1/α2-adrenoceptors results in systemic vasopressor responses, the purpose of this study was to investigate the specific role of α1- and α2-adrenoceptors mediating

Full Text available with Trip Pro

2017 The journal of headache and pain

5. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. (PubMed)

Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. To determine the safety of domperidone in the treatment of nausea associated with dihydroergotamine (DHE) infusion and headache.We audited our use of domperidone for the inpatient management of nausea, focusing on known safety concerns, particularly potential cardiac arrhythmias.We reviewed 103 consecutive admissions of 90 patients admitted for IV DHE by infusion. Most admissions were to treat

Full Text available with Trip Pro

2016 Neurology

6. Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. (PubMed)

Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. Transient headache exacerbation during IV dihydroergotamine (DHE) therapy of migraine may prompt clinicians to prematurely discontinue DHE therapy, potentially depriving patients of the full benefit of DHE infusion. In a recent Neurology® article, Eller et al. evaluated whether or not worsening headache during DHE infusion was associated with suboptimal medium-term headache outcomes.©

Full Text available with Trip Pro

2016 Neurology

7. Aprepitant for the management of nausea with inpatient IV dihydroergotamine. (PubMed)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine. To assess the efficacy and tolerability of oral aprepitant, a substance P/neurokinin A receptor antagonist, in controlling nausea associated with IV dihydroergotamine (DHE) administered for medically refractory migrainous headache in patients not responding to standard antiemetics or with a history of uncontrolled nausea with DHE.This was a retrospective chart review of prospectively collected hourly diary data

Full Text available with Trip Pro

2016 Neurology

8. Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. (PubMed)

Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. SEE DREIER DOI 101093/AWW112 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: For many decades a breakdown of the blood-brain barrier has been postulated to occur in migraine. Hypothetically this would facilitate access of medications, such as dihydroergotamine or triptans, to the brain despite physical properties otherwise restricting (...) their entry. We studied the permeability of the blood-brain barrier in six migraineurs and six control subjects at rest and during acute glyceryl trinitrate-induced migraine attacks using positron emission tomography with the novel radioligand (11)C-dihydroergotamine, which is chemically identical to pharmacologically active dihydroergotamine. The influx rate constant Ki, average dynamic image and time activity curve were assessed using arterial blood sampling and served as measures for receptor binding

Full Text available with Trip Pro

2016 Brain

9. Intranasal Dihydroergotamine

Intranasal Dihydroergotamine Intranasal Dihydroergotamine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Intranasal Dihydroergotamine (...) Intranasal Dihydroergotamine Aka: Intranasal Dihydroergotamine , Migranal II. Indications III. Efficacy Significant response in 30 minutes Migranal: 70% : 28% Reference IV. Dosing Prepare sprayer by inserting ampule and prime pump Use one spray each nostril May repeat x1 after 15 minutes (Total dose = 2mg) Maximum use is 2 times per week V. Advantages Lasts longer than intranasal less common than : 15% within 24 hours Less expensive than Intranasal ($16/dose) VI. Disadvantages Does not work as fast

2018 FP Notebook

10. Dihydroergotamine

Dihydroergotamine Dihydroergotamine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Dihydroergotamine Dihydroergotamine Aka (...) : Dihydroergotamine , DHE-45 II. Indications III. Dosing Parenteral Initial: 1 mg SC/IM/IV over 3-4 minutes Repeat: May repeat every 1 hour Maximum: 3 mg/day, 6 mg/week, 20 mg/month ( ) IV. Advantages Weaker (less Side Effects) No V. Adverse Effects Retroperitoneal fibrosis Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Dihydroergotamine." Click on the image (or right click) to open the source website in a new browser window. Related Studies

2018 FP Notebook

11. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. (PubMed)

Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. To evaluate whether headache exacerbation associated with IV dihydroergotamine (DHE) infusion predicts medium-term headache outcome in patients with chronic migraine.This was a retrospective chart review study of the UCSF Headache Center's use of IV DHE for chronic migraine from 2008 to 2012. Medium-term headache outcome was assessed at 6-week follow-up. Univariate and multivariate logistic regression

Full Text available with Trip Pro

2016 Neurology

12. Prophylaxis for postoperative deep-vein thrombosis. Synergistic effect of heparin and dihydroergotamine. (PubMed)

Prophylaxis for postoperative deep-vein thrombosis. Synergistic effect of heparin and dihydroergotamine. Randomized clinical trials in 300 patients undergoing major abdominal surgery or hip replacement arthroplasty were performed to investigate the efficacy of dihydroergotamine mesylate, heparin calcium, or a combination of dihydroergotamine with heparin in preventing postoperative deep-vein thrombosis (DVT). The diagnosis of DVT was established by an uptake test using fibrinogen labeled (...) with iodine 125; in patients undergoing hip replacement, phlebography was also employed to confirm or refute the presence of isotopic thrombi. The data indicate that the combination of dihydroergotamine and heparin is more effective than heparin or dihydroergotamine alone in preventing DVT.

1979 JAMA

13. Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. (PubMed)

Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. MAP0004 is an investigational product which delivers dihydroergotamine (DHE) through the lung via a breath-synchronized metered dose inhaler. The objective of this study was to compare the acute effects of orally inhaled and intravenous (IV) DHE to placebo on maximum change and area under the curve for pulmonary arterial systolic

Full Text available with Trip Pro

2013 Drug design, development and therapy

14. Assessment of the Consistency of Absorption of Dihydroergotamine Following Oral Inhalation: Pooled Results from Four Clinical Studies. (PubMed)

Assessment of the Consistency of Absorption of Dihydroergotamine Following Oral Inhalation: Pooled Results from Four Clinical Studies. MAP0004 is an investigational orally inhaled dihydroergotamine (DHE) delivered via a TEMPO(®) metered dose inhaler that was effective in the acute treatment of migraine in a large Phase 3 trial. Rapid and consistent absorption of DHE is important for efficacy in the acute treatment of migraine.The pharmacokinetic parameters from four recent clinical studies

2013 Journal of aerosol medicine and pulmonary drug delivery

15. Intranasal Dihydroergotamine

Intranasal Dihydroergotamine Intranasal Dihydroergotamine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Intranasal Dihydroergotamine (...) Intranasal Dihydroergotamine Aka: Intranasal Dihydroergotamine , Migranal II. Indications III. Efficacy Significant response in 30 minutes Migranal: 70% : 28% Reference IV. Dosing Prepare sprayer by inserting ampule and prime pump Use one spray each nostril May repeat x1 after 15 minutes (Total dose = 2mg) Maximum use is 2 times per week V. Advantages Lasts longer than intranasal less common than : 15% within 24 hours Less expensive than Intranasal ($16/dose) VI. Disadvantages Does not work as fast

2015 FP Notebook

16. Dihydroergotamine

Dihydroergotamine Dihydroergotamine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Dihydroergotamine Dihydroergotamine Aka (...) : Dihydroergotamine , DHE-45 II. Indications III. Dosing Parenteral Initial: 1 mg SC/IM/IV over 3-4 minutes Repeat: May repeat every 1 hour Maximum: 3 mg/day, 6 mg/week, 20 mg/month ( ) IV. Advantages Weaker (less Side Effects) No V. Adverse Effects Retroperitoneal fibrosis Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Dihydroergotamine." Click on the image (or right click) to open the source website in a new browser window. Related Studies

2015 FP Notebook

17. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers. (PubMed)

Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers. MAP0004 is an orally inhaled investigational drug containing dihydroergotamine (DHE). Although DHE has been used for 60 years with no reported cardiac arrhythmias, a thorough QT study had not previously been performed with DHE.The objective of this study was to assess the effects

2012 Clinical therapeutics

18. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. (PubMed)

MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. To evaluate the efficacy of MAP0004, an orally inhaled dihydroergotamine, for acute treatment of migraine when administered at various time points from within 1 hour to more than 8 hours after migraine onset.This post hoc subanalysis was conducted using data from 902 patients enrolled in a randomized, double-blind, placebo-controlled, 2-arm, phase 3, multicenter study conducted from

Full Text available with Trip Pro

2011 Mayo Clinic proceedings. Mayo Clinic

19. [Postural hypotension induced by neuroleptics: Rheographic study of the effects of corrective agents: Neosynephrine, dihydroergotamine, and heptaminol hydrochloride]. (PubMed)

[Postural hypotension induced by neuroleptics: Rheographic study of the effects of corrective agents: Neosynephrine, dihydroergotamine, and heptaminol hydrochloride]. 4439359 1975 02 27 2013 11 21 0040-5957 29 3 1974 May-Jun Therapie Therapie [Postural hypotension induced by neuroleptics: Rheographic study of the effects of corrective agents: Neosynephrine, dihydroergotamine, and heptaminol hydrochloride]. 421-34 Boismare F F Derrey D D Audisio M M Brocheriou J J fre Clinical Trial Comparative (...) Study English Abstract Journal Article Randomized Controlled Trial Hypotension posturale provoquée par les neuroleptiques: étude rhéographique de l'effet de correcteurs (néosynéphrine, dihydroergotamine et chlorhydrate d'heptaminol) France Therapie 0420544 0040-5957 0 Amino Alcohols 0 Tranquilizing Agents 1WS297W6MV Phenylephrine PR834Q503T Ergotamine IM S Amino Alcohols therapeutic use Ergotamine therapeutic use Hemodynamics Humans Hypotension, Orthostatic chemically induced drug therapy

1975 Therapie

20. [Controlled comparison of dihydroergotamine and etilofrin in orthostatic syndrome]. (PubMed)

[Controlled comparison of dihydroergotamine and etilofrin in orthostatic syndrome]. 26009 1978 07 24 2013 11 21 0025-8512 29 22 1978 Jun 02 Die Medizinische Welt Med Welt [Controlled comparison of dihydroergotamine and etilofrin in orthostatic syndrome]. 939-42 Garbe W E WE Clasen J J ger Clinical Trial Journal Article Randomized Controlled Trial Kontrollierter Vergleich von Dihydroergotamin und Etilefrin beim Orthostasesyndrom. Germany Med Welt 0376641 0025-8512 1WS297W6MV Phenylephrine (...) 436O5HM03C Dihydroergotamine ZB6F8MY53V Etilefrine IM S Adolescent Adult Dihydroergotamine therapeutic use Etilefrine therapeutic use Humans Hypotension, Orthostatic drug therapy Male Phenylephrine analogs & derivatives 78176364 1978 6 2 1978 6 2 0 1 1978 6 2 0 0 ppublish 26009

1978 Die Medizinische Welt

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>